Stocktoria
Adagene Inc. ADAG
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-02-09
Adagene Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $7.7M | $103,204 | $18.1M | $9.3M | $10.2M |
| R&D expense | $22.0M | $28.8M | $36.6M | $81.3M | $68.1M |
| Operating income | -$21.4M | -$36.0M | -$23.7M | -$83.9M | -$72.4M |
| Interest expense | — | — | $1.1M | $693,323 | $363,762 |
| Income tax | -$297,860 | -$17,553 | $1.7M | $459,055 | $1.7M |
| Net income | -$17.6M | -$33.4M | -$18.9M | -$80.0M | -$73.2M |
| EPS (diluted) | $-0.30 | $-0.59 | $-0.35 | $-1.48 | $-1.46 |
| Operating cash flow | -$15.7M | -$29.7M | -$28.5M | -$48.6M | -$43.4M |
| Cash & equivalents | $74.5M | $85.2M | $109.9M | $143.8M | $174.4M |
| Total assets | $78.3M | $89.3M | $115.7M | $152.4M | $189.5M |
| Total liabilities | $26.4M | $38.7M | $45.2M | $69.3M | $33.0M |
| Shareholders' equity | $35.3M | $50.5M | $70.6M | $83.1M | $156.6M |
Source: SEC EDGAR filings · CIK 0001818838 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.